Kingdomway(SZ:002626)2025-11-05 03:38Group 1: Financial Performance - In the first three quarters of 2025, the company achieved a revenue of CNY 2.604 billion, representing a year-on-year increase of 11.16% [2] - The net profit attributable to shareholders was CNY 361 million, showing a significant year-on-year growth of 63.47% [2] - The non-recurring net profit reached CNY 349 million, with a year-on-year increase of 56.22% [2] Group 2: Coenzyme Q10 Performance - Coenzyme Q10 remains a key product, with sales revenue, sales volume, and gross margin all increasing compared to the same period last year [2] - The expansion project for Coenzyme Q10 is progressing smoothly, with the annual production capacity expected to reach a significant volume upon full completion [2][3] - The market demand for Coenzyme Q10 is growing, driven by its applications in cardiovascular health and anti-aging [3] Group 3: Brand Performance - Doctor's Best, a mature brand established 35 years ago in the U.S., has seen revenue and profit growth in the first three quarters of the year [3] - The brand's products, including Coenzyme Q10, are popular among consumers, particularly in categories like cardiovascular health and anti-aging [3] - Doctor's Best is actively participating in promotional activities, such as the Double Eleven event, to enhance its market presence [3] Group 4: Strategic Outlook - The company focuses on biomanufacturing technology and aims to provide high-quality health solutions through innovation [3] - It is committed to building a complete industrial ecosystem, including raw material production, finished product manufacturing, and brand development [3] - Future strategies include strengthening various business segments and leveraging the advantages of a comprehensive supply chain [3]